GSK PLC-SPON ADR (GSK) Stock Fundamental Analysis

NYSE:GSK • US37733W2044

58.93 USD
+0.39 (+0.67%)
At close: Feb 13, 2026
59.34 USD
+0.41 (+0.7%)
After Hours: 2/13/2026, 8:14:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to GSK. GSK was compared to 191 industry peers in the Pharmaceuticals industry. GSK scores excellent on profitability, but there are some minor concerns on its financial health. GSK scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year GSK was profitable.
  • In the past year GSK had a positive cash flow from operations.
  • Each year in the past 5 years GSK has been profitable.
  • GSK had a positive operating cash flow in each of the past 5 years.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • GSK's Return On Assets of 9.35% is amongst the best of the industry. GSK outperforms 91.10% of its industry peers.
  • GSK has a Return On Equity of 34.90%. This is amongst the best in the industry. GSK outperforms 95.29% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 19.19%, GSK belongs to the top of the industry, outperforming 95.81% of the companies in the same industry.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • GSK has a better Profit Margin (17.50%) than 89.53% of its industry peers.
  • In the last couple of years the Profit Margin of GSK has declined.
  • The Operating Margin of GSK (27.47%) is better than 93.19% of its industry peers.
  • In the last couple of years the Operating Margin of GSK has grown nicely.
  • GSK has a better Gross Margin (72.67%) than 80.10% of its industry peers.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GSK is creating value.
  • GSK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.36 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GSK's Altman-Z score of 2.36 is fine compared to the rest of the industry. GSK outperforms 63.35% of its industry peers.
  • The Debt to FCF ratio of GSK is 3.73, which is a good value as it means it would take GSK, 3.73 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of GSK (3.73) is better than 87.43% of its industry peers.
  • A Debt/Equity ratio of 0.90 indicates that GSK is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.90, GSK is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.36
ROIC/WACC2.06
WACC9.33%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • GSK has a Current Ratio of 0.82. This is a bad value and indicates that GSK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GSK has a worse Current ratio (0.82) than 87.96% of its industry peers.
  • A Quick Ratio of 0.54 indicates that GSK may have some problems paying its short term obligations.
  • GSK's Quick ratio of 0.54 is on the low side compared to the rest of the industry. GSK is outperformed by 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • GSK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.84%.
  • GSK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.55% yearly.
  • GSK shows a small growth in Revenue. In the last year, the Revenue has grown by 4.11%.
  • The Revenue has been growing slightly by 6.05% on average over the past years.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • GSK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.00% yearly.
  • GSK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.96% yearly.
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.96%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.35, the valuation of GSK can be described as correct.
  • Based on the Price/Earnings ratio, GSK is valued cheaply inside the industry as 88.48% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.97, GSK is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.35 indicates a reasonable valuation of GSK.
  • GSK's Price/Forward Earnings ratio is rather cheap when compared to the industry. GSK is cheaper than 86.91% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, GSK is valued rather cheaply.
Industry RankSector Rank
PE 12.35
Fwd PE 11.35
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 91.10% of the companies listed in the same industry.
  • 87.43% of the companies in the same industry are more expensive than GSK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 18.24
EV/EBITDA 7.88
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • GSK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.4
PEG (5Y)3.48
EPS Next 2Y8.7%
EPS Next 3Y9.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • GSK has a Yearly Dividend Yield of 3.27%. Purely for dividend investing, there may be better candidates out there.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 1.18. GSK pays more dividend than 94.76% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, GSK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.27%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

  • GSK pays out 44.86% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK PLC-SPON ADR

NYSE:GSK (2/13/2026, 8:14:10 PM)

After market: 59.34 +0.41 (+0.7%)

58.93

+0.39 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners43.55%
Inst Owner Change204.24%
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap118.25B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts70
Price Target51.62 (-12.4%)
Short Float %0.89%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 3.27%
Yearly Dividend1.65
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)4.11%
PT rev (3m)14.72%
EPS NQ rev (1m)-4.83%
EPS NQ rev (3m)-3.66%
EPS NY rev (1m)-0.44%
EPS NY rev (3m)-0.46%
Revenue NQ rev (1m)-0.87%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE 12.35
Fwd PE 11.35
P/S 2.66
P/FCF 18.24
P/OCF 11.21
P/B 5.3
P/tB N/A
EV/EBITDA 7.88
EPS(TTM)4.77
EY8.09%
EPS(NY)5.19
Fwd EY8.81%
FCF(TTM)3.23
FCFY5.48%
OCF(TTM)5.26
OCFY8.92%
SpS22.19
BVpS11.12
TBVpS-5.02
PEG (NY)1.4
PEG (5Y)3.48
Graham Number34.55
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.36
F-Score9
WACC9.33%
ROIC/WACC2.06
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.96%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year30.24%
EBIT Next 3Y13.85%
EBIT Next 5Y7.82%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.81% in the next year.